title: Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.
abstract: Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract disease in infants, young children, and the elderly worldwide, and despite decades of effort, there remains no safe and effective vaccine. RSV modifies the host immune response during infection by CX3C chemokine mimicry adversely affecting pulmonary leukocyte chemotaxis and CX3CR1+ RSV-specific T-cell responses. In this study we investigated whether immunization of mice with RSV G protein polypeptides from strain A2 could induce antibodies that block G protein-CX3CR1 interactions of both RSV A and B strains. The results show that mice immunized with RSV A2 G polypeptides generate antibodies that block binding of RSV A2 and B1 native G proteins to CX3CR1, and that these antibodies effectively cross-neutralize both A and B strains of RSV. These findings suggest that vaccines that induce RSV G protein-CX3CR1 blocking antibodies may provide a disease intervention strategy in the efforts to develop safe and efficacious RSV vaccines.
authors.affiliation: College of Veterinary Medicine, Department of Infectious Disease, University of Georgia, Athens, Georgia, USA.
authors.forename: Youngjoo
authors.initials: Y
authors.lastname: Choi
authors.forename: Caleb S
authors.initials: CS
authors.lastname: Mason
authors.forename: Les P
authors.initials: LP
authors.lastname: Jones
authors.forename: Jackelyn
authors.initials: J
authors.lastname: Crabtree
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Jorquera
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Tripp
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D000073883:CX3C Chemokine Receptor 1; D002460:Cell Line; D020523:Chemokines, CX3C / Q000378:metabolism*; D003429:Cross Reactions; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D011485:Protein Binding / Q000187:drug effects*; D019707:Receptors, Chemokine / Q000378:metabolism*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000145:classification / Q000276:immunology*; D014611:Vaccination; D014760:Viral Fusion Proteins / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000073883:CX3C Chemokine Receptor 1; C095235:CX3CR1 protein, human; D020523:Chemokines, CX3C; C502275:G glycoprotein, Respiratory syncytial virus; D019707:Receptors, Chemokine; D014760:Viral Fusion Proteins